Theravance Biopharma (TBPH) Enterprise Value (2016 - 2025)
Theravance Biopharma (TBPH) has disclosed Enterprise Value for 12 consecutive years, with -$177.2 million as the latest value for Q3 2025.
- On a quarterly basis, Enterprise Value fell 93.91% to -$177.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$177.2 million, a 93.91% decrease, with the full-year FY2024 number at -$40.1 million, changed N/A from a year prior.
- Enterprise Value was -$177.2 million for Q3 2025 at Theravance Biopharma, up from -$338.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$40.1 million in Q4 2024 to a low of -$486.8 million in Q3 2022.
- A 5-year average of -$194.3 million and a median of -$167.5 million in 2023 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: surged 72.47% in 2023, then plummeted 252.63% in 2025.
- Theravance Biopharma's Enterprise Value stood at -$216.2 million in 2021, then crashed by 51.46% to -$327.5 million in 2022, then skyrocketed by 59.08% to -$134.0 million in 2023, then surged by 70.08% to -$40.1 million in 2024, then crashed by 341.92% to -$177.2 million in 2025.
- Per Business Quant, the three most recent readings for TBPH's Enterprise Value are -$177.2 million (Q3 2025), -$338.8 million (Q2 2025), and -$130.9 million (Q1 2025).